Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
### Primary Indications
* Gastroesophageal reflux disease (GERD) - symptomatic relief and healing of erosive esophagitis.
* Zollinger-Ellison syndrome and other hypersecretory conditions.
* Part of *Helicobacter pylori* eradication regimens.
### Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily. Duration of treatment varies (e.g., 4-8 weeks).
* **Maintenance of Healing Erosive Esophagitis:** 40 mg orally once daily. Some patients may need 20 mg daily.
* **Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Starting dose typically 40 mg orally or intravenously every 8 hours. Doses may be adjusted up to 240 mg daily (divided doses) based on response.
* ***H. pylori* Eradication:** Typically a component of multi-drug therapy (e.g., amoxicillin and clarithromycin) for 7-14 days. Common regimens include pantoprazole 40 mg orally twice daily.
### Pediatric Dosing
* **GERD/Erosive Esophagitis:**
* **1 month to <5 years:** 10 mg orally once daily.
* **5 years to <12 years:** 20 mg orally once daily.
* **≥12 years:** 40 mg orally once daily.
* *Note: Intravenous dosing in pediatric patients is less established and may require specialist consultation.*
### Dose Adjustments
* **Hepatic Impairment:** Reduce daily dose to 20 mg orally once daily for chronic use.
### Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
### Adverse Effects
* **Common:** Diarrhea, headache, nausea, abdominal pain, dizziness, flatulence.
* **Serious/Long-term Concerns:**
* *Clostridioides difficile*-associated diarrhea.
* Bone fractures (hip, wrist, spine) with long-term, high-dose use.
* Vitamin B12 deficiency.
* Hypomagnesemia (can be severe).
* Acute interstitial nephritis.
* Fundic gland polyps.
### Key Drug Interactions
* **Antiretrovirals (e.g., rilpivirine, atazanavir):** Pantoprazole can decrease their absorption; avoid coadministration.
* **Methotrexate:** PPIs may increase methotrexate levels; consider a temporary interruption of pantoprazole.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution with drugs like clopidogrel (reduced effectiveness), though clinical significance is debated.
### Monitoring
* Monitor for signs and symptoms of *C. difficile* infection.
* Consider magnesium levels with prolonged therapy (typically >3 months), especially if taking concomitant diuretics or digoxin.
* Assess for signs of bone fracture risk with long-term use.
* Monitor for effectiveness in healing esophagitis or controlling hypersecretory conditions.
### Clinical Pearls
* Administer orally 30-60 minutes before a meal.
* Pantoprazole is generally considered less likely to inhibit CYP2C19 compared to omeprazole, but caution is still warranted.
* Long-term PPI use is associated with increased risks; use the lowest effective dose for the shortest duration necessary.
* IV administration is an option when oral route is not feasible.
***
**Disclaimer:** This information is intended for clinical pharmacists and healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for definitive patient management. Dosing may vary based on institutional protocols and individual patient factors.
